Cutaneous T-cell Lymphoma
📧 Sign up to get email alerts when something new happens for Cutaneous T-cell Lymphoma.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS withdrawal · 2016-12-01Clinical Trial Update: Ph1 Volasertib Plus Romidepsin in R/R PTCL and CTCL [Phase 1]
This update reports the withdrawal of a Phase 1 study evaluating volasertib plus romidepsin for relapsed/refractory peripheral T-cell lympho…
-
CLINICAL_TRIALS trial_result · 2016-11-29Clinical Trial Update: A-dmDT390-bisFv(UCHT1) Immunotoxin Therapy for Patients With Cutaneous T-Cell Lymphoma (CTCL) [Phase 2]
Phase 2 trial of A-dmDT390-bisFv(UCHT1) immunotoxin for cutaneous T-cell lymphoma (CTCL) has completed, with results from the study summariz…
-
CLINICAL_TRIALS trial_result · 2016-11-03Clinical Trial Update: A Study of the Histone Deacetylase Inhibitor (HDACi) Quisinostat (JNJ-26481585) in Patients With Previously Treated Stage Ib-IVa Cutaneous T-cell Lymphoma [Phase 2]
Phase 2 study update of the HDAC inhibitor quisinostat in previously treated Cutaneous T-Cell Lymphoma (Stage Ib-IVa) has completed.
-
CLINICAL_TRIALS trial_result · 2016-10-31Clinical Trial Update: Everolimus in Treating Cutaneous T-cell Lymphoma [Phase 2]
A Phase 2 trial of everolimus for cutaneous T-cell lymphoma was terminated, with results posted in 2016.
-
CLINICAL_TRIALS trial_result · 2016-10-20Clinical Trial Update: Efficacy, Safety and Tolerability Study of SHAPE in IA, IB or IIA Cutaneous T-cell Lymphoma [Phase 2]
This clinical trial update discusses a Phase 2 study of SHAPE in IA, IB or IIA Cutaneous T-Cell Lymphoma assessing efficacy, safety and tole…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS research · 2016-08-30Clinical Trial Update: Low Dose Total Skin Electron Beam Treatment (TSEBT) Followed by Maintenance Valchlor for Patients With Mycosis Fungoides [Phase 2]
A Phase 2 study investigating low-dose total skin electron beam therapy followed by maintenance Valchlor (mechlorethamine gel) for patients …
-
FDA approval · 2016-07-27FDA Approved: ISTODAX — Supplemental Application (Celgene Corporation)
The FDA approved a supplemental application for Istodax (romidepsin) from Celgene Corporation.
-
CLINICAL_TRIALS trial_result · 2016-06-24Clinical Trial Update: Analysis of Cutaneous and Hematologic Disorders by High-Throughput Nucleic Acid Sequencing
This clinical trial update reports termination of the study NCT01556828, which analyzed cutaneous and hematologic disorders using high-throu…
-
CLINICAL_TRIALS trial_result · 2016-04-18Clinical Trial Update: Early Diagnosis of Mycosis Fungoides [NA]
The document provides an update on a clinical trial investigating early diagnosis of mycosis fungoides, a form of cutaneous T-cell lymphoma,…
-
CLINICAL_TRIALS trial_result · 2016-04-13Clinical Trial Update: CD5789 in Early Cutaneous T-Cell Lymphoma (CTCL) [Phase 1]
Phase 1 study of CD5789 in early cutaneous T-cell lymphoma (CTCL) has completed its Phase 1 portion.
-
FDA approval · 2016-04-08FDA Approved: VALCHLOR — Supplemental Application (Helsinn Therapeutics (U.S.), Inc.)
FDA approved a supplemental application for Valchlor (mechlorethamine hydrochloride) from Helsinn Therapeutics (U.S.), Inc.
-
CLINICAL_TRIALS trial_result · 2016-03-24Clinical Trial Update: Safety, Pharmacodynamics (PD), Pharmacokinetics (PK) Study of SHP141 in 1A, 1B, or 2A Cutaneous T-Cell Lymphoma (CTCL) [Phase 1]
Phase 1 study assessing safety, pharmacodynamics, and pharmacokinetics of SHP141 in patients with cutaneous T-cell lymphoma (CTCL); results …
-
CLINICAL_TRIALS trial_result · 2016-03-11Clinical Trial Update: Long-term Use of Romidepsin in Patients With CTCL
Clinical trial update on long-term use of romidepsin in patients with cutaneous T-cell lymphoma. The study is completed and sponsored by Nor…
-
CLINICAL_TRIALS trial_result · 2016-02-17Clinical Trial Update: Combination Drug Study of Bexarotene and Rosiglitazone to Treat CTCL [Phase 2]
A Phase 2 trial investigating a combination of bexarotene and rosiglitazone for cutaneous T-cell lymphoma has been completed, with results p…
-
CLINICAL_TRIALS trial_result · 2016-02-17Clinical Trial Update: Bortezomib in Treating Patients With Relapsed or Refractory Cutaneous T-Cell Lymphoma [Phase 2]
Phase 2 trial of bortezomib for relapsed or refractory cutaneous T-cell lymphoma has completed enrollment with results posted.
-
CLINICAL_TRIALS trial_result · 2016-02-12Clinical Trial Update: Depsipeptide to Treat Patients With Cutaneous T-Cell Lymphoma and Peripheral T-Cell Lymphoma [Phase 2]
A Phase 2 study evaluated depsipeptide (romidepsin) for cutaneous T-cell lymphoma and peripheral T-cell lymphoma. The trial has completed wi…
-
FDA approval · 2015-12-17FDA Approved: ZOLINZA — Supplemental Application (Merck Sharp & Dohme LLC)
FDA approved a supplemental application for Zolinza (vorinostat) from Merck Sharp & Dohme LLC.
-
FDA label_change · 2015-10-29FDA Approved: VALCHLOR — Supplemental Application (Helsinn Therapeutics (U.S.), Inc.)
FDA approved a supplemental application for VALCHLOR (mechlorethamine hydrochloride), resulting in labeling updates for the product.
-
FDA approval · 2015-09-14FDA Approved: TARGRETIN — Supplemental Application (Bausch Health US, LLC)
The FDA approved a supplemental application for TARGRETIN (bexarotene) submitted by Bausch Health US, LLC.
-
CLINICAL_TRIALS trial_result · 2015-09-03Clinical Trial Update: Sorafenib Tosylate in Treating Patients With Recurrent Aggressive Non-Hodgkin's Lymphoma [Phase 2]
Phase 2 trial evaluating sorafenib tosylate in patients with recurrent aggressive non-Hodgkin lymphomas has completed, with results posted i…
-
FDA approval · 2015-07-29FDA Approved: TARGRETIN — Supplemental Application (Bausch Health US, LLC)
FDA approved a supplemental application for TARGRETIN (bexarotene) submitted by Bausch Health US, LLC. This action represents a supplemental…
-
CLINICAL_TRIALS trial_result · 2015-07-08Clinical Trial Update: A Study of APO866 for the Treatment of Cutaneous T-cell Lymphoma [Phase 2]
Phase 2 clinical trial evaluating APO866 for Cutaneous T-cell Lymphoma has completed.
-
CLINICAL_TRIALS withdrawal · 2015-06-04Clinical Trial Update: Therapeutic Efficacy of Topical Sirolimus in Early Stage Cutaneous T-cell Lymphoma (CTCL) [Phase 2]
A Phase 2 clinical trial evaluating topical sirolimus for early-stage cutaneous T-cell lymphoma has been withdrawn.
-
CLINICAL_TRIALS research · 2015-04-29Clinical Trial Update: Analysis of Genes Present in Cutaneous T-cell Lymphoma Cells [NA]
This clinical trial update reports an analysis of genes expressed in cutaneous T-cell lymphoma cells, providing genomic insights into this l…
-
CLINICAL_TRIALS trial_result · 2015-03-25Clinical Trial Update: Effect of Denileukin Diftitox on Immune System in CTCL Patients
This completed trial update reports on the effects of denileukin diftitox on the immune system in patients with cutaneous T-cell lymphoma, i…